Japan's Sosei Group Corp. regained the global rights to certain treatments for migraines and severe headaches.
The Tokyo-based pharmaceuticals company partnered with Israel's Teva Pharmaceutical Industries Ltd. to develop treatments known as calcitonin gene-related peptide, or CGRP, receptor antagonists that block a small protein found in high levels in the sensory nerves of the head and neck during migraine attacks.
Teva has now decided to terminate the 2015 partnership as part of a portfolio prioritization to stabilize its global generics business and to launch new specialty products.
Teva is already seeking EU and U.S. approval for its own anti-CGRP product, fremanezumab, also known as TEV-48125, to treat migraines.
The returning drug candidates include HTL0022562, which was to be evaluated in a phase 1 clinical trial later this year.
Sosei will undertake a detailed review of the programs and update the market on the new expected timing for HTL0022562's entry into phase 1 clinical trials, following a formal handover from Teva.
